Ask AI
ProCE Banner Series

From Target to Tolerability: Nurse-Led Strategies for Optimizing Bispecific Antibody Therapy in Multiple Myeloma

Join us virtually for this certified “live from ONS” virtual symposium in conjunction with the 2026 Oncology Nursing Society (ONS) Congress to gain expert insights into emerging efficacy and safety data on bispecific antibodies currently used to manage multiple myeloma to mitigate risk and improve patient outcomes.

  ANCC
Who Should Attend

This activity has been designed to meet the educational needs of community oncology nurses, nurse practitioners, and other healthcare professionals caring for patients with multiple myeloma.

All Events

From Target to Tolerability: Nurse-Led Strategies for Optimizing Bispecific Antibody Therapy in Multiple Myeloma

Upcoming Events

May

15

2026

8:00 AM - 9:00 AM Central Time (CT)

Virtual

Topics

Multiple Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The activity aims to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and other healthcare professionals in educating and caring for patients with multiple myeloma receiving bispecific antibody therapy.

Target Audience
This activity has been designed to meet the educational needs of community oncology nurses, nurse practitioners, and other healthcare professionals caring for patients with multiple myeloma.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with multiple myeloma
  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials evaluating currently available and emerging bispecific antibodies
  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma
  • Educate patients with myeloma and their caregivers on how to identify and mitigate risk and thereby improve outcomes

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191